查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2006214

轉染技術市場：依產品、方法、應用和最終用戶分類－2026-2032年全球市場預測

Transfection Technologies Market by Product, Method, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，轉染技術市場價值將達到 13.7 億美元，到 2026 年將成長到 14.9 億美元，到 2032 年將達到 24.9 億美元，複合年成長率為 8.88%。

主要市場統計數據
基準年 2025 13.7億美元
預計年份：2026年 14.9億美元
預測年份 2032 24.9億美元
複合年成長率 (%) 8.88%

簡述轉染技術的科學基礎、商業性重要性及新興機會。

轉染技術在分子生物學和治療方法創新交叉領域發揮核心作用，為從基礎基因表現研究到先進的細胞和基因療法等一系列研究提供支持。現代實驗室利用多種轉染技術將核酸和其他生物分子導入細胞，從而實現基因編輯、蛋白質生產、疫苗研發和細胞株建構。鑑於平台創新步伐的加快和應用範圍的不斷擴大，對於學術界、工業界和臨床研究領域的決策者而言，系統性地概述各種技術模式、實際權衡取捨以及相關人員的優先事項至關重要。

分析了由創新、監管趨勢和不斷變化的研究重點所驅動的，正在重塑轉染技術格局的變革性變化。

轉染領域瞬息萬變，多種變革力量匯聚一堂，重塑研究流程與商業化路徑。載體設計、脂質體配方和物理遞送平台的創新，拓展了分子生物學家可用的工具。同時，基因組編輯和細胞療法的同步發展，推動了對可靠且可擴展的轉染解決方案的需求。此外，針對治療應用領域良好生產規範 (GMP) 和品管的日益嚴格的監管要求，也迫使供應商和終端用戶重新評估其產品規格和文件記錄規範。

評估 2025 年美國關稅措施將如何重塑供應鏈、採購慣例、調查工作流程和國際合作。

美國在2025年實施或修訂的關稅措施，將進一步增加依賴跨境分銷設備、試劑及相關耗材的機構的營運複雜性。進口關稅的變化可能會推高高度專業化設備和單一來源試劑的總成本，迫使採購團隊重新審查與供應商的契約，協商長期協議，並探索其他替代方案，例如在地採購和區域分銷合作夥伴。因此，供應鏈的可視性和庫存策略在實驗室風險管理中變得至關重要，有助於防止供應鏈中斷造成的業務中斷，並緩解成本的急劇上升。

透過整合產品、方法、應用和最終用戶觀點的細分洞察，我們指導所有相關人員。

細分洞察揭示了不同產品類型、調查方法、應用領域和最終用戶群在需求和購買行為方面的顯著差異。在產品細分中，儀器和試劑/試劑盒提供了截然不同的價值提案。儀器需要資本規劃、服務模式和更長的認證週期，而試劑和試劑盒則更注重批間一致性、保存期限和通訊協定檢驗。這種差異導致了不同的採購週期和對供應商的期望；儀器往往涉及較少但單筆金額更高的交易，而試劑則需要穩定的供應保障和品管文件。

重點區域洞察，檢驗美洲、歐洲、中東和非洲以及亞太地區的趨勢如何影響技術採用、協作和供應鏈策略。

區域趨勢影響著美洲、歐洲、中東和非洲（EMEA）以及亞太地區的技術採納路徑、合作模式和供應鏈結構。在美洲，一個研究生態系統已經形成，它匯集了世界一流的學術機構、強大的生物技術產業和活躍的臨床開發項目，從而推動了對尖端儀器和檢驗的試劑組的強勁需求。這些使用者通常優先考慮與現有工作流程的整合以及供應商的應對力，並且傾向於選擇能夠提供本地支援和快速服務能力的供應商。

從企業層面深入了解生技公司和研究機構的競爭定位、夥伴關係關係、創新管道和商業化重點。

企業級趨勢揭示了供應商如何透過創新管道、策略夥伴關係和商業化策略來滿足客戶的獨特需求，從而實現差異化競爭。主要企業越來越重視端到端解決方案，將儀器、檢驗試劑和標準化通訊協定結合，以減輕用戶的整合負擔。這種方法提高了可重複性，縮短了新方法的採用時間，同時也為訂閱和服務模式創造了機會，從而持續產生收入並客戶維繫。

針對產業領導者的具體建議，重點在於研發投資、供應鏈韌性、監管參與和商業化策略。

產業領導者應採取多管齊下的策略，在增強供應鏈和監管韌性的同時，提昇技術差異化能力。各組織應優先進行有針對性的研發投資，以解決尚未解決的性能差距，例如提高對難以轉染細胞類型的遞送效率和降低細胞毒性，同時確保研發藍圖符合最終用戶的檢驗要求。對品質系統和監管文件的同步投入將降低治療應用臨床試驗的門檻，並增強對策略夥伴的吸引力。

調查方法，詳細介紹資料來源、分析框架、定性專家意見以及用於確保可靠見解的檢驗方法。

本分析整合了以下三個面向的檢驗：對科學和採購領域領導者的定性訪談、對產品文獻和監管指南的系統性回顧，以及體現採購和供應鏈應對措施的營運案例研究。該調查方法旨在平衡專家見解與文獻檢驗，以捕捉轉染技術的技術細微差別以及儀器和試劑市場的商業性現實。專家訪談提供了有關技術應用促進因素、品質期望和營運限制的背景信息，而產品文件和檢驗資料集則用於比較性能特徵和支援系統。

將研究、臨床和商業相關人員。

本文提出的綜合分析重點闡述了技術創新、營運韌性和監管準備如何共同決定轉染技術在整個研究和治療生態系統中的部署成敗。其策略意義包括：產品開發需與特定應用的驗證要求保持一致；加大對品質和文件的投入以支持轉化應用；以及設計能夠反映學術界、臨床和工業界客戶多樣化採購行為的商業化模式。這些優先事項對於正在從概念驗證(PoC) 階段過渡到可重複且可擴展的工作流程的機構至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 轉染技術市場：依產品分類

  • 裝置
  • 試劑和試劑盒

第9章 轉染技術市場：依方法分類

  • 生物轉染
    • 質體DNA
    • 病毒載體
  • 化學轉染
    • 磷酸鈣轉染
    • 脂質體
  • 物理轉染
    • 生物轉染/基因
    • 電穿孔
    • 顯微注射

第10章 轉染技術市場：依應用分類

  • 細胞株構建
  • CRISPR和基因編輯
  • 基因治療
  • 蛋白質生產
  • 疫苗接種

第11章 轉染技術市場：依最終用戶分類

  • 學術和研究機構
  • 合約研究組織（CRO）
  • 醫院和診斷檢測機構
  • 製藥和生物技術公司

第12章 轉染技術市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 轉染技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 轉染技術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國轉染技術市場

第16章：中國轉染技術市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Epoch Life Science, Inc.
  • FUJIFILM Wako Pure Chemical Corporation
  • GeneCopoeia Inc.
  • Geno Technology, Inc.
  • Horizon Discovery Group plc by PerkinElmer, Inc.
  • Lonza Group
  • Maxcyte Inc.
  • Merck KGaA
  • Nepa Gene Co., Ltd.
  • OriGene Technologies, Inc.
  • OZ Biosciences SAS
  • Polyplus-transfection SA by Sartorius AG
  • Polysciences, Inc.
  • Promega Corporation
  • Qiagen NV
  • Reprocell Inc.
  • SignaGen Laboratories LLC
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-B16853779807

The Transfection Technologies Market was valued at USD 1.37 billion in 2025 and is projected to grow to USD 1.49 billion in 2026, with a CAGR of 8.88%, reaching USD 2.49 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.37 billion
Estimated Year [2026] USD 1.49 billion
Forecast Year [2032] USD 2.49 billion
CAGR (%) 8.88%

A concise introduction outlining the scientific foundations, commercial importance, and emerging opportunities within transfection technologies

Transfection technologies occupy a central role at the interface of molecular biology and therapeutic innovation, underpinning work from fundamental gene expression studies to advanced cell and gene therapies. Contemporary laboratories rely on a spectrum of transfection approaches to introduce nucleic acids and other biomolecules into cells, enabling gene editing, protein production, vaccine development, and cell line engineering. Given the accelerating pace of platform innovations and expanding application scope, an organized introduction that clarifies technology modalities, practical trade-offs, and stakeholder priorities is essential for decision-makers across academia, industry, and clinical research.

This introduction frames transfection technologies in scientific and operational contexts. It highlights the methodological diversity that influences experimental design, translation timelines, and procurement strategies. It also clarifies how reagent and instrument considerations interact with regulatory pathways and partnership models. By situating technological capabilities alongside end-user requirements, the narrative sets the stage for pragmatic prioritization, helping research directors, procurement leads, and commercialization strategists align resources to accelerate reproducible outcomes and translational impact.

Analysis of transformative shifts reshaping the transfection technology landscape driven by innovation, regulatory trends and evolving research priorities

The transfection landscape is in flux as several transformative forces converge to reshape research workflows and commercialization pathways. Innovations in vector design, lipid formulations, and physical delivery platforms have broadened the toolkit available to molecular biologists, while parallel advances in genome editing and cell therapy have elevated demand for reliable, scalable transfection solutions. At the same time, regulatory expectations around good manufacturing and quality control for therapeutic applications are tightening, prompting vendors and end users to re-evaluate product specifications and documentation practices.

Concurrently, shifting investment patterns and cross-sector partnerships are accelerating technology diffusion. Strategic collaborations between reagent developers, instrument manufacturers, and therapeutic developers are creating bundled solutions that reduce integration friction for translational programs. Moreover, growing emphasis on reproducibility and open science is encouraging standardized protocols and validated kits that reduce experimental variability. Together, these shifts point to a landscape where technological differentiation, regulatory readiness, and the ability to support end-to-end workflows determine which solutions gain sustained adoption across research, clinical, and industrial settings.

Assessment of how 2025 United States tariff actions are reshaping supply chains, procurement practices, research workflows, and international collaboration

Tariff actions enacted or modified by the United States in 2025 have introduced an additional layer of operational complexity for organizations that rely on cross-border flows of instruments, reagents, and ancillary supplies. Changes in import duties can elevate landed costs for highly specialized instruments and single-source reagents, prompting procurement teams to re-evaluate supplier agreements, negotiate longer-term contracts, and examine alternatives such as local sourcing or regional distribution partners. Consequently, supply chain mapping and inventory strategies have become more central to laboratory risk management to prevent disruptive stockouts and mitigate sudden cost escalations.

Beyond procurement, tariff shifts influence research workflows and collaboration models. Higher input costs may encourage greater consolidation of experiments to optimize reagent utilization and favor approaches that reduce per-experiment consumable use. In addition, collaborations that depend on cross-border transfer of biological materials and equipment now require more detailed contract provisions addressing customs liabilities and cost-sharing. Regulatory compliance remains a parallel concern, as changes in the origin of inputs can affect documentation and qualification processes for materials used in therapeutic development. Ultimately, while tariff adjustments do not alter the scientific imperatives driving transfection adoption, they do shape the economic and logistical decisions that determine how quickly and efficiently organizations can deploy new technologies.

Segmentation insights integrating product, method, application, and end-user perspectives to guide R&D priorities and procurement decisions across stakeholders

Segmentation insights reveal meaningful variance in needs and purchasing behavior across product categories, methodological approaches, application areas, and end-user groups. Within product segmentation, instruments and reagents & kits present distinct value propositions: instruments require capital planning, service models, and longer qualification cycles, whereas reagents and kits emphasize batch consistency, shelf life, and protocol validation. This dichotomy drives different procurement cadences and supplier expectations, with instruments often involving fewer transactions of higher value and reagents needing repeatable supply assurances and quality control documentation.

Method-based segmentation further differentiates demand. Biological transfection modalities, encompassing plasmid DNA workflows and viral vector delivery, are characterized by regulatory scrutiny and process controls suited to therapeutic applications. Chemical transfection approaches, including calcium phosphate and lipofection techniques, offer flexible bench-scale options that prioritize ease of use and reproducibility for routine experiments. Physical transfection methods such as biolistic delivery, electroporation, and microinjection address specific cell types and experimental constraints, often commanding specialized instrumentation and operator expertise. Application-driven segmentation shows that cell line development, CRISPR and gene editing, gene therapy, protein production, and vaccination each impose unique performance and validation requirements, influencing the selection of methods and suppliers. End-user segmentation indicates divergent priorities: academic and research institutes prioritize cost-effectiveness and protocol flexibility; contract research organizations emphasize throughput, reproducibility, and documented quality systems; hospitals and diagnostic laboratories require validated, regulatory-compliant inputs; and pharmaceutical and biotechnology companies prioritize scalability, regulatory alignment, and supplier risk management. Taken together, these segmentation lenses provide a framework for aligning product development, commercialization, and support services to the specific needs of each stakeholder group.

Key regional insights examining how dynamics in the Americas, EMEA, and Asia-Pacific influence technology adoption, collaborations, and supply chain strategies

Regional dynamics shape technology adoption pathways, collaboration models, and supply chain configurations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, the research ecosystem combines world-class academic institutions, a robust biotech sector, and active clinical development programs, driving strong demand for both cutting-edge instruments and validated reagent kits. These users often prioritize integration with existing workflows and supplier responsiveness, leading to preference for vendors with local support and rapid service capabilities.

In Europe, Middle East & Africa, regulatory harmonization and cross-border collaboration influence procurement and validation practices, while national research priorities can create pockets of specialized demand. The need for documentation, QA/QC traceability, and compliance with regional regulatory frameworks encourages suppliers to provide detailed technical files and to engage in localized support. Asia-Pacific presents a heterogeneous landscape where high-volume manufacturing capacity, fast-growing research investment, and diverse regulatory regimes co-exist. Organizations in this region increasingly pursue local manufacturing partnerships and regional distribution strategies to manage costs and lead times. Across all regions, cross-border collaborations and global clinical programs necessitate coordinated supplier strategies that balance lead-time risks, customs considerations, and support infrastructures to sustain research continuity and clinical translation.

Company-level insights into competitive positioning, partnerships, innovation pipelines, and commercialization priorities across biotechnology and research firms

Company-level dynamics reveal how vendors differentiate through innovation pipelines, strategic partnerships, and commercialization approaches that address distinct customer needs. Leading firms increasingly prioritize end-to-end solutions that couple instruments with validated reagents and standardized protocols to reduce integration burden for users. This approach enhances reproducibility and shortens onboarding timelines for new methods, while also creating opportunities for subscription and service models that provide recurring revenue and customer retention.

Partnerships and alliances play a central role in accelerating market entry for novel delivery platforms and reagents. Developers of specialized reagents often collaborate with instrument manufacturers and application-focused labs to co-develop validated workflows and to demonstrate performance in real-world use cases. Moreover, companies that invest in robust regulatory documentation and quality management systems position themselves to support clinical translation and commercial manufacturing. Investment in customer support capabilities, training programs, and digital resources further differentiates providers by enabling faster adoption and greater user confidence, particularly among organizations transitioning from academic proof-of-concept work to clinical and industrial applications.

Actionable recommendations for industry leaders focusing on R&D investment, supply chain resilience, regulatory engagement, and commercialization strategies

Industry leaders should adopt a multi-dimensional strategy that strengthens technological differentiation while reinforcing supply chain and regulatory resilience. Organizations can prioritize targeted R&D investments that address unmet performance gaps-such as increasing delivery efficiency for hard-to-transfect cell types or reducing cytotoxicity-while ensuring that development roadmaps align with end-user validation requirements. Parallel investments in quality systems and regulatory documentation will reduce time-to-clinic friction for therapeutic applications and enhance attractiveness to strategic partners.

Operationally, stakeholders should diversify procurement channels and cultivate regional distribution relationships to mitigate tariff and logistics risks. This includes qualifying alternate suppliers, maintaining strategic buffer inventories for critical reagents, and negotiating service-level agreements for instrument maintenance. From a commercial perspective, companies should expand training and technical-support offerings to lower adoption barriers, develop bundled solutions that simplify workflow integration, and design pricing models that reflect the distinct procurement behaviors of academic, CRO, clinical, and industry customers. Finally, proactive regulatory engagement and participation in standards-setting initiatives will help align product design with evolving compliance expectations and support smoother translational pathways.

Research methodology overview detailing data sources, analytical frameworks, qualitative expert inputs, and validation approaches used to ensure robust insights

This analysis synthesizes evidence from primary qualitative interviews with scientific and procurement leaders, structured reviews of product literature and regulatory guidance, and triangulation against operational case studies that illustrate procurement and supply chain responses. The methodological approach balances expert input with documentary validation to capture both the technical nuances of transfection methods and the commercial realities of instrument and reagent markets. Expert interviews provided context on adoption drivers, quality expectations, and operational constraints, while product documentation and validation datasets were used to compare performance characteristics and supportability.

To ensure robustness, findings were validated through cross-checking with publicly available regulatory frameworks and institutional procurement practices, and by reviewing representative vendor claims against published application notes and peer-reviewed studies. The analytical framework emphasizes reproducibility, practical applicability, and relevance to strategic decision-making, with explicit attention to mitigating bias through the use of multiple independent information sources and transparent documentation of assumptions and inference pathways. This methodology supports actionable conclusions and targeted recommendations tailored to research, clinical, and commercial stakeholders.

Conclusive synthesis of strategic implications, priority actions, and evolving opportunities across research, clinical, and commercial stakeholders

The synthesis presented here emphasizes that technological innovation, operational resilience, and regulatory preparedness jointly determine successful adoption of transfection technologies across research and therapeutic ecosystems. Strategic implications include the need to align product development with application-specific validation requirements, to invest in quality and documentation that support translational use, and to design commercialization models that reflect the differing purchasing behaviors of academic, clinical, and industrial customers. These priorities are critical for organizations seeking to move from proof-of-concept to reproducible, scalable workflows.

Priority actions include strengthening supplier relationships and logistical planning to reduce exposure to tariff and customs volatility, investing in targeted R&D that addresses high-value performance gaps, and enhancing customer enablement through training and validated workflows. As the landscape continues to evolve, stakeholders who combine technical excellence with operational agility and proactive regulatory engagement will be best positioned to capture the long-term scientific and commercial benefits associated with advanced transfection platforms. This integrated perspective supports informed decision-making and lays out a clear set of focus areas for organizational leaders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transfection Technologies Market, by Product

  • 8.1. Instruments
  • 8.2. Reagents & Kits

9. Transfection Technologies Market, by Method

  • 9.1. Biological Transfection
    • 9.1.1. Plasmid DNA
    • 9.1.2. Viral Vectors
  • 9.2. Chemical Transfection
    • 9.2.1. Calcium Phosphate Transfection
    • 9.2.2. Lipofection
  • 9.3. Physical Transfection
    • 9.3.1. Biolistic Transfection/Gene Guns
    • 9.3.2. Electroporation
    • 9.3.3. Microinjection

10. Transfection Technologies Market, by Application

  • 10.1. Cell Line Development
  • 10.2. CRISPR & Gene Editing
  • 10.3. Gene Therapy
  • 10.4. Protein Production
  • 10.5. Vaccination

11. Transfection Technologies Market, by End-User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations (CROs)
  • 11.3. Hospitals & Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Transfection Technologies Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transfection Technologies Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transfection Technologies Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Transfection Technologies Market

16. China Transfection Technologies Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. Epoch Life Science, Inc.
  • 17.8. FUJIFILM Wako Pure Chemical Corporation
  • 17.9. GeneCopoeia Inc.
  • 17.10. Geno Technology, Inc.
  • 17.11. Horizon Discovery Group plc by PerkinElmer, Inc.
  • 17.12. Lonza Group
  • 17.13. Maxcyte Inc.
  • 17.14. Merck KGaA
  • 17.15. Nepa Gene Co., Ltd.
  • 17.16. OriGene Technologies, Inc.
  • 17.17. OZ Biosciences SAS
  • 17.18. Polyplus-transfection SA by Sartorius AG
  • 17.19. Polysciences, Inc.
  • 17.20. Promega Corporation
  • 17.21. Qiagen NV
  • 17.22. Reprocell Inc.
  • 17.23. SignaGen Laboratories LLC
  • 17.24. Takara Bio Inc.
  • 17.25. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSFECTION TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CALCIUM PHOSPHATE TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CALCIUM PHOSPHATE TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CALCIUM PHOSPHATE TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY LIPOFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY LIPOFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY LIPOFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLISTIC TRANSFECTION/GENE GUNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLISTIC TRANSFECTION/GENE GUNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLISTIC TRANSFECTION/GENE GUNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CRISPR & GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CRISPR & GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CRISPR & GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PROTEIN PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PROTEIN PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PROTEIN PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VACCINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VACCINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VACCINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 149. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 151. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 172. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 173. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 175. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 176. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 180. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 182. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 183. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 184. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)